Clinical trials for drugs, devices and other treatments or interventions Obesity Dual-target weight-loss drug is 47% more effective than its rival The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to...
Trust us to provide personalized treatments for infectious diseases and all things wound care, call us now 706-739-7789!
Semaglutide Provides Superior Body Weight Reduction Across Sustain 1–5 Clinical TrialsEmanuela Mello Ribeiro CavalariNovo Nordisk Farmaceutica do BrasilIldiko LingvayNovo Nordisk Farmaceutica do BrasilJrg LüdemannNovo Nordisk Farmaceutica do BrasilMichel Marre...
Semaglutide Therapy Improves Liver Histology in MASH Medscape Medical NewsMay 12, 2025 GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis. UK Government to Criminalise Misuse of ‘Nurse’ Title ...
Gastrointestinal adverse events were more often reported with semaglutide (n = 30) than with placebo (n = 15). Semaglutide treatment for 24 weeks resulted in a clinically meaningful reduction in albuminuria in patients with overweight/obesity and non-diabetic CKD. ClinicalTrials.gov ...
Understand the effect of clinical trials and real-world evidence in healthcare on validating new treatments and providing proof of their effectiveness.
Semaglutide is a peptidic GLP-1 receptor agonist that may regulate the aggregation of Aβ in AD. GLP-1 receptors are involved in cognition, synaptic transmission in hippocampal neurons, and cell apoptosis; thus, they may serve as targets for exploring candidate drugs with neuroprotective and cognit...
Diabetes Dialogue: Semaglutide for MASH in ESSENCE Trial, With Arun Sanyal, MD Diabetes Dialogue: CATALYST Reveals High Prevalence of Hypercortisolism in T2D Diabetes Dialogue: Oral GLP-1 Orforglipron in ACHIEVE-1 Trial Skin of Color Savvy: News Update—Discussing the AAD Clinical Image Collection...
The main advantage of semaglutide is seen in the evidence from previous clinical trials assessing the safety of the drug and additional benefits: semaglutide had mild-to-moderate gastrointestinal adverse events such as diarrhea, nausea, and vomiting, in a dose-dependent manner. These events usually ...
Semaglutide is a peptidic GLP-1 receptor agonist that may regulate the aggregation of Aβ in AD. GLP-1 receptors are involved in cognition, synaptic transmission in hippocampal neurons, and cell apoptosis; thus, they may serve as targets for exploring candidate drugs with neuroprotective and cognit...